

CURRICULUM VITAE MIRIAM LICHTNER

Part I General Information

Full Name: Miriam Lichtner

E-mail: miriam.lichtner@uniroma1.it

Spoken Languages: Italian, English, and French

POSITION TITLE: Associate Professor of Infectious Disease at Department of Public Health and Infectious Disease, Sapienza University of Rome

Part II EDUCATION/TRAINING

TYPE	Year	Institution	FIELD OF STUDY
University graduation	1989-1994	Sapienza University of Rome	Medicine and Surgery
Post-graduate studies	1995	University of Bari	Cellular immunology and microbiology
Speciality	1996-1999	Sapienza University of Rome, Policlinico Umberto I	Infectious Disease
Pre-doctorate training	1999-2000	ISS (Istituto Superiore di sanità)	AIDS fellowship
Ph.D.	2001-2004	Sapienza University of Rome	Experimental Immunology and infectious
Licensure	1995	Sapienza University of Rome	Licensure for medical clinical practice
Foreign experience	2001-2002	Institut Cochin de Génétique Moléculaire (ICGM), Paris, France	HIV immunology

Part III- Appointments

IIIA- Academic Appointment

Start	End	Institution	Position
1996	2000	Sapienza University	Resident
2002	2003	<ul style="list-style-type: none">Institut Cochin de Génétique Moléculaire (ICGM), Paris, France	Foreign Resercher
2009	2018	Sapienza University Department of Public Health and Infectious Disease	Assistant Professor
2019	ongoing	Sapienza University Department of Public Health and Infectious Disease	Associate Professor

IIIB Other Appointments

Start	End	Institution	Position
2003	2008	Policlinico Umberto I Hospital of Rome	Temporary contract as MD, Infectious Disease Specialist
2008	2017	Azienda Sanitaria of Latina, SM Goretti Hospital	Permanent contract as MD, Infectious Disease Specialist
2017	Ongoing	Azienda Sanitaria of Latina, SM Goretti Hospital	Director of the Unit of Infectious Disease

Part IV- Teaching experiences:

Start	End	Institution	Lecture/Course
2005	2006	Sapienza University	Infectious Disease at Corso di Laurea in Scienze Infermieristiche Q (Terracina);

2007	2008	Sapienza University	Infectious Disease at Corso di Laurea in Igiene Dentale (Terracina);
2008	Ongoing	Sapienza University	Infectious Disease at Corso di Laurea E of Medicine (Latina)
2009	Ongoing	Sapienza University	Infectious Disease at Corso di Laurea in Scienze Infermieristiche Q (Terracina);
2010	Ongoing	Sapienza University	School of Infectious Disease Speciality
2010	Ongoing	Sapienza University	PhD in Infectious Diseases, Microbiology and Public Health
2011	2016	Sapienza University	Infectious Disease at Corso di Laurea A of Medicine (Rome)
2011	Ongoing	Sapienza University	Infectious Disease at Corso di Laurea in Scienze Infermieristiche R , Sapienza University of Roma (Latina)
2015	Ongoing	Sapienza University	Infectious Disease at the Course “F” of Medicine and Surgery International Medical School Sapienza University of Rome

Part V- Society memberships, Awards and Honors

Since 1999-:	Member of Italian Society of Infectiuos Disease (SIMIT)
Since 1997	Member of Study group of Italian Cohort of Naïve HIV Subjects I.Co.N.A
Since 2002	Member of Study group of EUROSIDA/D.A.D.

Since 2012	Member of the Scientific Board of Italian Cohort of Naïve HIV Subjects I.Co.N.A.
Since 2012	Member of the Panel of Italian HIV Guidelines Working Group.
Since 2004	Member of the Italian National Focal Point , Istituto Superiore di Sanità
2007	Member of European Academies Science Advisory Council (EASAC): “Impact of migration on infectious diseases in Europe”;
2010	Award of American Society for Microbiology (ASM). ICAAC Program Committee Award in the area of Immunology of Infection
2012	Award for the best oral presentation at Workshop: “HIV, Cells of Macrophage/Dendritic Lineage, and Other Reservoirs: Pathogenic and Therapeutic Implications “Stresa, May 10-12, 2012
2012	AWARD OF THE NATIONAL SCIENTIFIC QUALIFICATION AS ASSOCIATE PROFESSOR
2016	Ethical award at Digital Health program fellowship 2016
2017	AWARD OF THE NATIONAL SCIENTIFIC QUALIFICATION AS FULL PROFESSOR
2018	Member of Polio free Comitee of Health Ministry (nomina 306483304 19/11/2018)
2021	Ethical award “Mauro Moroni” at Digital Health program fellowship 2019
2021	Honor by Lazio Region for the commitment in the Fight against COVID-19 in Latina province
2021	Award “Frumento d’oro” for the best women involved in health work
2021	Honor as “Cavaliere della Repubblica Italiana” for the commitment during pandemia

Part VI- Funding Information (grant as PI-investigator or I-investigator)

Year	Title	Program	Grant Value
1997-1998	I	Effetto di potenti combinazioni antiretrovirali sul sistema immune innato: studio della funzionalità dei macrofagi e neutrofili Programma nazionale di ricerca sull'AIDS	28 milioni lire
2006	I	“Gli studenti italiani e non italiani e l’infezione da HIV/AIDS: un’indagine psico-socio-comportamentale nelle scuole medie inferiori e superiori.)- VI Programma nazionale di ricerca sull'AIDS	25.000 euro
2007	I	Infezione da HIV e popolazione migrante: reale accesso ai servizi psico-socio-sanitari e fruibilità delle cure” Convenzione 534R/2-2	30.000
2009	PI	prot. C26F09W89H Ricerca dell'Ateneo Federato delle Scienze delle Politiche Pubbliche e Sanitarie SPPS Progetto di ricerca di Facoltà, Ruolo delle cellule dendritiche nell'infezione da HIV: controllo virologico e immuno-attivazione	5000 euro
2009	I	Istituto Superiore di Sanità Pharmacological Modulation of HIV Associated Inflammation: Role of Matrix Metalloproteinases as Therapeutic Targets Role	30.000
2010	I	Istituto Pasteur Fondazione Cenci Bolognetti: IMMUNOPATHOGENESIS OF HIV INFECTION: STUDY OF INNATE IMMUNITY AND DENDRITIC CELLS	30.000

2010	PI	prot. C26A1023NB II anno di finanziamento per il progetto dal titolo Ruolo delle cellule dendritiche nell'infezione da HIV: controllo virologico e immuno-attivazione	5000
2011	PI	prot. C26A11M32E Cellule dendritiche, infezione da HIV e differenze di genere: ruolo delle DC infiammatorie e della risposta interferonica	5000
2012	I	Istituto Superiore di Sanità Conv. 3M08/2 "Applicazione del modello operativo per favorire interventi di prevenzione dell'infezione da HIV e della tubercolosi in fasce di popolazioni migranti"	40.000
2013	PI	Beyond HIV-related microbial translocation hypothesis. Oltre la traslocazione microbica nell'infezione da HIV: caratterizzazione dell'immunoattivazione residua nei pazienti HIV positivi in terapia soppressiva e ruolo di altre coinfezioni (CMV, virus epatitici)" prot. C26A13WYZ7	5000
2014	PI	prot. C26A14HFB7 " Interazione HIV/CMV and immunological milieu.	5000
2014	PI	Fellowship Program 2014: Il successo terapeutico nel soggetto HIV infetto: valutazione dei determinanti immunovirologici e del grado di "frailty" nell'interazione HIV/CMV Role	25000
2015	PI	prot. C26A15JYA9 "Neurocognitive frailty in	5000

		HIV-1 infected subjects on effective antiretroviral treatment (ART): role of chronic CMV infection, residual immune activation and monocytes subsets.	
2016		Progetto finanziamento per la ricerca di Ateneo 2016: ROBUSTNESS evaluation as a tool to identify HIV+ aviremic patients suitable for simplification of Follow up	5000
2016		Fellowship Digital Health Program 2016 Doctor Apollo: il BOT entra nella pratica clinica come interfaccia medico-paziente-caregiver nella gestione a lungo termine della persona HIV+"	30.000
2017	PI	Progetto Ateneo Progetto finanziamento per la ricerca di Ateneo 2017: Innate immunity and immune activation in HIV/HCV coinfectd subjects undergoing DAA	5000
2017	PI	Assegno di ricerca nel Progetto Ateneo: Innate immunity and immune activation in HIV/HCV coinfectd subjects undergoing DAA	23.000
2017	PI tutor	Fellowship Program 2017- "Ruolo dello shedding vaginale del CMV nella donna HIV positiva: implicazioni immunologiche, ormonali e cliniche"	25000
2017	I	Fellowship Digital Health Program 2017: Digital ambient media come strumenti di sensibilizzazione e	35.000

		prevenzione dell'infezione da HIV: Amare con Sapienza	
2016	PI	RETROSPECTIVE MONOCENTRIC STUDY ON DALBAVANCIN IN THE MANAGEMENT OF ABSSSIS IN REAL PRACTICE” STUDIO MONOCENTRICO RETROSPETTIVO SU DALBAVANCINA NELLA GESTIONE DELLE ABSSSIS NELLA PRATICA CLINICA	7000
2018	PI	Studio Multicentrico “Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir plus Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 to 6 (The MARS study)	8000
2017	PI	“Attuali modelli europei di pratica clinica relativi alla gestione delle infezioni cutanee: valutare l'incidenza delle infezioni cutanee, la percentuale delle infezioni batteriche acute della cute e della struttura cutanea (ABSSSI) e la relativa gestione clinica e terapeutica”	6000
2018	PI	Hepadisk Validation Study - Epidemiological study for Hepatitis C QoL questionnaire validation” Non Interventional Study No. 10967	6500
2019	PI	Progetto Ateneo: “Mucosal Immunity in HIV-1 infected women undergoing effective antiretroviral therapy:	10.000

		biomarkers and clinical determinants”	
2019	PI	Fellowship Program 2019-ERADICHIAMOCI: Progetto di micro-eradicatione HCV tra gli utilizzatori di sostanze nel polo pontino	30.000
2020	PI	• TOCIVID-19 - Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. EudraCT Number	NO
2020	PI	Progetto Ateneo: “Ruolo dell’immunità innata nell’infezione da SARS-COV2 in una corte di pazienti con polmonite da COVID: biomarkers e correlati clinici	10.000
2021	PI	“Studio COVITAR multicentrico di fase II/III, randomizzato, stratificato, cieco all’osservatore e controllato con placebo per valutare l’efficacia, la sicurezza e l’immunogenicità del vaccino GRAd-COV2 negli adulti di età pari o superiore a 18 anni.” Protocollo RT-CoV-2_01 – EudraCT Number: 2020-005915-39	130.000

Part VII- Research Activities

Keywords	Brief description
HIV infection	<p>At the beginning of my research activity I produced several publications on opportunistic infection such as <i>Rhodococcus equi</i> infection and neuroAIDS (J Infect Dis 1994, AIDS 1995, AIDS 1996). Since 1999 I focus my attention on innate immunity in particular neutrophils and monocytes (AIDS 1999; J Infect Dis. 2000 and apoptosis (AIDS 2000; Biochem Pharmacol. 2003; AIDS Res Hum Retroviruses 2004). Starting from my PhD training and with the collaboration of the French Laboratory I developed a new methodology to assess blood dendritic cells by flow cytometry (Methods Mol Biol. 2008) and conducted several studies to understand the clinical use of DC assessment in particular in determining cardiovascular risk, virological failure and tuberculosis reactivation (Clin Exp Immunol. 2006, Curr HIV Res. 2008, Atherosclerosis 2009). Also we described for the first time the role of HIV-1 and Type I IFN on the cytotoxic activity of DC (J Infect Dis. 2005; AIDS Res Hum Retroviruses. 2004). Recently an expansion of myeloid cells were observed and described in subjects on stable HAART (V. Curr HIV Res. 2016).</p> <p>Other experimental studies were carried out on CCR5 and CCR5 inhibitors always regarding innate immunity (J Acquir Immune Defic Syndr. 2010, PLoS One. 2011, Clin Exp Immunol. 2011).</p> <p>A constant collaboration with the laboratory of the Biochemical and Neuro laboratory of Bari University was developed with several studies on the role of matrix metalloproteinases and neuropathogenesis in HIV (AIDS. 2007, Brain. 2004).</p> <p>More recently I conducted several studies on the role of CMV/HIV coinfection in determining a worse clinical outcome using the ICONA cohort data(J Infect Dis. 2015, J Infect Dis. 2015, JAIDS 2016). In the ICONA cohort I participated in several clinical studies in particular on HAART effect, pregnancy and CD4/CD8 ratio (Lancet HIV. 2015, PLoS One. 2015, J Acquir Immune Defic Syndr. 2014). Moreover other studies are focussed on the effect of HIV infection on vaginal mucosal immunity in women together with evaluation of female sexual dysfunction.</p>
Tuberculosis	<p>During these years, I conducted several studies on TB pathogenesis, clinical presentation and diagnosis. In particular several papers were published on the Interferon gamma Release Assay in special population (Tuberculosis 2011 PLoS One. 2009, Br J Dermatol. 2013). Recently in my lab, we proposed a new immunologic algorithm to distinguish latent and active TB (J Immunol Res. 2015, BMC 2016).</p>
Hepatitis	<p>Several studies were carried out on HBV, in particular on pathogenesis and virological aspects (World J Gastroenterol. 2011, Hepatology. 2015, J Antimicrob Chemother. 2012, World J Gastroenterol. 2011, J Antimicrob Chemother. 2012). Regarding HCV infection, I studied HCV/HIV interaction, immunopathogenesis and new DAA impact (<i>HIV Clin Trials</i>. 2002, AIDS. 2007, Int J Mol Sci. 2014, Int J Mol Sci. 2016; Clin Microbiol Infect. 2016). In the last years the effect of DAA treatment on immune activation and inflammation was the main focus (Clin Res Hepatol Gastroenterol. 2017, Plos 2017).</p>

Migrants and Developing Country studies	<p>I participated in several projects on migration and Developing Country regarding HIV. I founded the Mingha Project in Camerun that is an ongoing program for the Prevention of Mother to Child transmission of HIV (AIDS Res Hum Retrovir. 2012; AIDS. 2009; AIDS Res Hum Retroviruses. 2008)</p> <p>Moreover I collaborate to several studies on migrants in Italy as a risk group for HIV and TB infection (Infection. 2014 Ann Ig. 2013; Emerg Infect Dis. 2009).</p>
SARS-COV 2	<p>During the current pandemy, I conducted clinical and experimental studies in patients affected by SARS- CoV2 infection. Several studie was focussed on the identification of the risk factors for the severe form in the context of metabolic comorbidities, such as diabetes, metabolic syndrome and cardiovascular events (Diabetes Res Clin Pract. 2020 Nov). Regarding therapy we studied the effect of immunomodulators agents such us tocilizumab and steroids (J Transl Med. 2020 Oct 21, PLoS One. 2021 Feb 23;Plos One 2021 Sep 1). Finally the immunological pattern of COVID-19 patients were characterized studying natural immunity with NK cells, dendritic and monocytes subpopulations. An important reduction was found in the more severe patients together with an increase of sCD163 and sCD14 factors (Front Immunol. 2021 Feb 26, Clin Immunol. 2021 Jan;222). Other projects are ongoing, on the specific immune response in frayl SARS-CoV2 vaccinated subjects.</p>
Nosocomial infection and infection control	<p>Studies on effective approaches in contrasting nosocomial infections in particular KPC spreading in the hospital focussing on ICU, haematology and neurosurgery wards. Antibiotic Stewardship implementation.</p>

Part VIII- Social Activities (third mission)

Year	typology	activity
2003-2006	HIV and Sexual Transmitted Disease Prevention in High School	Organizzazione of a network of formation courses by peer educator methodology in 30 High Schools in Rome. Collaboration with ANLAIDS and MINGA association
2008-2010	HIV and Sexual Transmitted Disease Prevention in Seocndary School	Organizzazione of a network of formation courses by peer educator methodology in 15 Secondary Schools in Rome. Collaboration with ARCHE' association
2008	HIV prevention among non	Survey and campaign of sensibilization in secondary schools in Rome

	italian student in secondart schools	
2009	Transcultural HIV prevention in youth	Project of HIV prevention in schools in a rural area in Camerun with a twinning between a school in Rome and in Dschang
2010-ongoing	HIV prevention promotion	HIV testing activities implementation in several initiatives involving youngs, women, adults, citizen of Latina. Hospital and non hospital activities. Medical students involvement as peers.
2019	Mother to child infections prevention	Open day activities during February 2019 with a active offer of complete screening for sexual active women in Latina
2020	HIV prevention	Ufficial Involvement of Latina Municipality in the international network of Fast Track cities
2021	HIV prevention and quality of life implementation	Creation of a Check Point activity community based with point of care testing (POCT) and counselling in Latina
2019-ongoing	Public support in COVID-19 pandemic	TV and newspaper Interviews to increase awareness, prevention and vaccination in SARS-CoV emergencies

Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers (international)	213	Scopus	1994	2021
Papers (national)	5			
Books [scientific]	1			
Books [teaching]	3			

Total Impact factor	993,57	Scopus
ScopusTotal Citations	7511	Scopus
Average Citations per Product	35	Scopus
Hirsch (H) index	38	Scopus
Normalized H index*	1,4 (1,52**)	Scopus

*H index divided by the academic seniority.

** including two maternity periods

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

- 1) **Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia.**

Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, Marocco R, Kertusha B, Siccardi G, Del Borgo C, Curtolo A, Ajassa C, Iannetta M, Ciardi MR, Mastroianni CM, *Lichtner M*. Front Immunol. 2021 Feb 26, Cit: **7, IF 5,085**

- 2) **Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate to-severe COVID-19 pneumonia: a retrospective cohort study Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.**

Russo G, Solimini A, Zuccalà P, Zingaropoli MA, Carraro A, Pasculli P, Perri V, Marocco R, Kertusha B, Del Borgo C, Del Giudice E, Fondaco L, Tieghi T, D'Agostino C, Oliva A, Vullo V, Ciardi MR, Mastroianni CM, *Lichtner M*. PLoS One. 2021 Sep 10;16 Cit: **NA, IF: 3,041**

- 3) **Impact of SARS CoV-2 pandemic on carbapenemase-producing Klebsiella pneumoniae prevention and control programme: convergent or divergent action?**

Belvisi V, Del Borgo C, Vita S, Redaelli P, Dolce P, Pacella D, Kertusha B, Carraro A, Marocco R, De Masi M, Mastroianni C, *Lichtner M*; IPC Program Working Group. J Hosp Infect. 2021 Mar; 109:29-31. Cit: **6, IF: 3,27**

- 4) **Is Albumin Predictor of Mortality in COVID-19?** Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, Pirro M, Pignatelli P, *Lichtner M*, Carraro A, Cipollone F, D'Ardes D, Pugliese F, Mastroianni CM. Antioxid Redox Signal. **2020 Jun 22 Cit: 55, IF: 7,61**

- 5) **Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.**

Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, *Lichtner M*. PLoS One. **2017 Jun 21;12(6):e0179400. Cit. 26 IF 3,055**

- 6) **Cytomegalovirus coinfection is associated with an increased risk of severe non- AIDS-defining events in a large cohort of HIVinfected patients.**

- Lichtner M*, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moiola M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. *J Infect Dis.* **2015** Jan 15;211(2):178-86. doi:10.1093/infdis/jiu417. **Cit: 109 I.F: 5.84**
- 7) **Multifunctional Analysis of CD4+ T-Cell Response as Immune- Based Model for Tuberculosis Detection.**
Lichtner M, Mascia C, Sauzullo I, Mengoni F, Vita S, Marocco R, Belvisi V, Russo G, Vullo V, Mastroianni CM. *J Immunol Res.* **2015**; 2015:217287. doi: 10.1155/2015/217287. **Cit. 12, IF: 4,066**
- 8) **CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.**
Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, *Lichtner M*, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. *Lancet HIV.* **2015** Mar;2(3):e98-106. **Cit 145, IF 9.84**
- 9) **Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.**
Mastroianni CM, *Lichtner M*, Mascia C, Zuccalà P, Vullo V. *Int J Mol Sci.* **2014** May 26;15(6):9184- 208. doi: 10.3390/ijms15069184. PMID: 24865485 **Cit 56, IF 2.33**
- 10) **Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection.**
Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, Mascia C, Del Borgo C, Mengoni F, Sauzullo I, d'Ettorre G, D'Agostino C, Massetti AP, Vullo V. *PLoS One.* **2011**;6(5):e19872. Epub 2011 May 19. **I.F: 4,09 , Citations: 23**
- 11) **Current trends in management of hepatitis B virus reactivation in the biologic therapy era.**
Mastroianni CM, *Lichtner M*, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. *World J Gastroenterol.* **2011** Sep 14;17(34):3881-7, **IF: 2,471 citations: 46**
- 12) **Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count.**
Lichtner M, Rossi R, Rizza MC, Mengoni F, Sauzullo I, Massetti AP, Luzi G, Hosmalin A, Mastroianni CM, Vullo V. *Curr HIV Res.* 2008 Jan;6(1):19-27. **Impact factor: 2.49, Citations: 22**
- 13) **Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment**
Lichtner M, Cuomo MR, Rossi R, Strano S, Massetti AP, Mastroianni CM, Vullo V. *Atherosclerosis.* 2009 Jun; 204(2):e1-3. Epub 2008 Dec 30. **Cit: 12 Impact Factor: 5,16**
- 14) **Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.**

Lichtner M, Rossi R, Mengoni F, Vignoli S, Colacchia B, Massetti AP, Kamga I, Hosmalin A, Vullo V, Mastroianni CM. Clin Exp Immunol. 2006 Feb;143(2):329-37. **Cit: 37 I.F: 4,33**

15) **HIV-1 infected dendritic cells induce apoptotic death in infected and uninfected CD4+ T lymphocytes**

Miriam Lichtner, Concepción Marañón, Pierre-Olivier Vidalain, Olga Azocar, Daniel Hanau, Pierre Lebon, Marianne Burgard, Christine Rouzioux, Vincenzo Vullo, Hideo Yagita, Chantal Rabourdin-Combe, Christine Servet, Anne Hosmalin AIDS Res Hum Retroviruses. 2004 Feb;20(2):175-82. **I.F: 2.082, Citations: 71**

16) **HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.**

Lichtner M, Mengoni F, Mastroianni CM, Sauzullo I, Rossi R, De Nicola M, Vullo V, Ghibelli L. Apoptosis. 2006 May;11(5):781-7. **Cit: 16, IF: 3.44**



Rome 01/10/2021